No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Barclays downgraded GSK's consumer health spinoff Haleon on Tuesday to 'equalweight' from 'overweight' as it said questions marks persist over the US and there are "a few new clouds on the horizon".
The bank noted that the US accounts for 34% of sales and said it is seeing slower category growth and destocking.
"Haleon is overweight declining US drug stores," it said, adding that the US was the reason Haleon lowered its 2025 organic sales growth guidance to around 3.5%. Barclays said it still sees short-term risks.
"Haleon has a new US head but we move to the sidelines as we await the plan," it said.
At 0915 BST, the shares were down 2.8% at 346.78p.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.